Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
Abstract Background The optimal treatment for polypoidal choroidal vasculopathy (PCV) is still under debate. Little knowledge is known about the treatment effect of “1+pro re nata(PRN)” treatment regimen for PCV. The aim of this study was to compare the outcomes of photodynamic therapy (PDT), intrav...
Main Authors: | Kunbei Lai, Ying Li, Lijun Zhou, Xiaojin Zhong, Chuangxin Huang, Fabao Xu, Lin Lu, Jian Ge, Chenjin Jin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-06-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12886-018-0801-7 |
Similar Items
-
Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab
by: Zeynep Alkin, et al.
Published: (2016-12-01) -
Comparison of Two-Year Outcome of Photodynamic Therapy in Combination with Intravitreal Aflibercept or Ranibizumab for Polypoidal Choroidal Vasculopathy
by: Hsin-Yu Weng, et al.
Published: (2021-01-01) -
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
by: Xiaoya Gu, et al.
Published: (2019-07-01) -
AFLIBERCEPT IN TREATMENT OF RESISTANT POLYPOID CHOROIDAL VASCULOPATHY: SHORT-TERM RESULTS
by: E. K. Pedanova, et al.
Published: (2017-12-01) -
Two-Year Results of Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy; A Real Life Experience
by: Sibel Ahmet, et al.
Published: (2017-12-01)